Security
Immutep Limited American Depositary Shares · IMMP
IMMPNASDAQotherCurrentCIK 1506184Updated Nov 3, 2026
Name history
Prima BioMed Ltd · through Dec 1, 2017
IMMP price & chart
Loading TradingView…
NASDAQ:IMMP on TradingView ↗About the company
Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. The Company is a pioneer in the understanding and advancement of therapeutics related to the Lymphocyte Activation Gene-3 (LAG-3)/MHC Class II immune control mechanism, and its diversified product portfolio harnesses the ability of this mechanism to stimulate or suppress the immune system. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
In the news
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines – IMMP ↗
Portnoy Law Firm Announces Class Action on Behalf of Immutep Limited Investors ↗
Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · AUDSource
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossAUD | -61,434,165Source | -42,716,625Source | -39,896,348Source | -32,210,826Source |
| Additional Financial Items | ||||
| AdjustmentsForCurrentTaxOfPriorPeriodAUD | — | — | — | 148,303Source |
| AdjustmentsForSharebasedPaymentsAUD | 1,163,543Source | 1,796,286Source | 2,001,572Source | 1,486,841Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsAUD | 3,165,899Source | -283,057Source | -296,038Source | — |
| GeneralAndAdministrativeExpenseAUD | 8,644,503Source | 8,852,615Source | 8,679,840Source | 7,210,123Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesAUD | 0Source | 0Source | 0Source | 34Source |
| InterestPaidClassifiedAsFinancingActivitiesAUD | 36,759Source | 30,328Source | 8,818Source | 9,712Source |
| InterestPaidClassifiedAsOperatingActivitiesAUD | 35,545Source | 30,009Source | 20,541Source | — |
| InterestReceivedClassifiedAsOperatingActivitiesAUD | 3,716,331Source | 3,695,594Source | 917,997Source | 224,656Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesAUD | 270,666Source | 226,494Source | 211,974Source | 222,536Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesAUD | 225,414Source | 903,154Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueAUD | 10,331,373Source | 7,838,625Source | 5,200,128Source | 6,758,073Source |
| Additional Financial Items | ||||
| AdministrativeExpenseAUD | 3,554,058Source | 4,229,578Source | 3,711,789Source | 3,321,923Source |
| BasicEarningsLossPerShareAUD/shares | -0.04Source | -0.04Source | -0.04Source | -0.04Source |
| CurrentTaxExpenseIncomeAUD | — | — | — | 34Source |
| DeferredTaxExpenseIncomeAUD | — | — | — | 0Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossAUD | 0Source | 0Source | 0Source | 0Source |
| DepreciationAndAmortisationExpenseAUD | 2,389,524Source | 2,261,858Source | 2,061,819Source | 2,063,462Source |
| DepreciationRightofuseAssetsAUD | 255,110Source | 248,764Source | 202,605Source | 224,406Source |
| DilutedEarningsLossPerShareAUD/shares | -0.04Source | -0.04Source | -0.04Source | -0.04Source |
| EmployeeBenefitsExpenseAUD | 10,772,257Source | 8,824,161Source | 6,527,725Source | 4,966,304Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesAUD | 1,163,543Source | 1,796,286Source | 2,001,572Source | 1,486,841Source |
| ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsedAUD | 5,580Source | 4,705Source | 5,782Source | 9,518Source |
| ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedAUD | 3,216Source | 3,165Source | 6,539Source | 2,376Source |
| FinanceCostsAUD | 37,078Source | 30,594Source | 20,401Source | 92,430Source |
| GeneralAndAdministrativeExpenseAUD | 8,644,503Source | 8,852,615Source | 8,679,840Source | 7,210,123Source |
| IncomeTaxExpenseContinuingOperationsAUD | 0Source | 0Source | 0Source | 34Source |
| InterestExpenseOnLeaseLiabilitiesAUD | 36,283Source | 30,272Source | 8,678Source | 10,462Source |
| NetForeignExchangeLossAUD | 1,529,309Source | — | 0Source | 0Source |
| ProfitLossAttributableToOwnersOfParentAUD | -61,434,165Source | -42,716,625Source | -39,896,348Source | -32,210,826Source |
| ProfitLossBeforeTaxAUD | -61,434,165Source | -42,716,625Source | -39,896,348Source | -32,210,792Source |
| ResearchAndDevelopmentExpenseAUD | 49,778,916Source | 31,472,063Source | 28,793,385Source | 25,337,538Source |
| RevenueFromInterestAUD | 5,287,209Source | 3,882,757Source | 938,999Source | 224,520Source |
Filing attachments
d183841dex991.htm · 6-K · 2026-11-02
Exhibit 99.1 ASX / Media Release Immutep Quarterly Activities Report & Appendix 4C Q1 FY27 Immutep intends to focus the registration-directed clinical development of efti on HNSCC in patients with CPS <1 and the neoadjuvant setting of STS, with preparations for future clinical trials underway and study start targeted for H2 CY27. IMP761, the Company’s agonist anti-LAG-3 antibody for autoimmune diseases, is now a co-priority alongside efti and will be the subject of a late breaking po…
Read attachment ↗d51422dex991.htm · 6-K · 2026-10-29
Exhibit 99.1 Immutep Receives A$2.16 million French R&D Tax Incentive SYDNEY, AUSTRALIA - 28 October, 2026 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that it has received a cash payment of €1.36 million (approximately A$2.16 million) from the French Government under its Crédit d’Impôt Recherche (CIR) research tax incentive program, for eligible R&D activities conducted…
Read attachment ↗d109552dex416.htm · 20-F · 2026-10-23
Exhibit 4.16 CONFIDENTIAL CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT WAS OMITTED BY MEANS OF MARKING SUCH INFORMATION WITH BRACKETS (“[***]”) BECAUSE THE IDENTIFIED CONFIDENTIAL INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL LICENSE AGREEMENT T HIS L ICENSE A GREEMENT (the “Agreement”) is entered into as of December 8, 2025 (the “Effective Date”), by and between I MMUTEP S.A.S., a company having an address at Parc Les Algorithmes, B…
Read attachment ↗d36112dex991.htm · 6-K · 2026-10-14
Exhibit 99.1 Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement SYDNEY, AUSTRALIA - October 13, 2026 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that it has received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated 12 October 2026 (US Eastern Time), confirming that the Company has regained com…
Read attachment ↗d79097dex991.htm · 6-K · 2026-09-22
Exhibit 99.1 Change to American Depositary Share Ratio SYDNEY, AUSTRALIA - September 21, 2026 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces a change to the ratio of its American Depositary Shares (“ADSs”), which are quoted on the Nasdaq Global Market under the symbol IMMP. With effect from the commencement of trading on the Nasdaq Global Market on 28 September 2026 (US Easte…
Read attachment ↗d127093dex991.htm · 6-K · 2026-09-11
Exhibit 99.1 Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”) Future registration-directed clinical development of efti is intended to focus on head and neck squamous cell carcinoma (HNSCC) in patients with negative PD-L1 expression (Combined Positive Score (CPS) < 1) and the neoadjuvant setting of soft tissue sarcoma (STS). ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────…
Read attachment ↗